비교리스트

 카트 문의
시장보고서
상품코드
1511948

약물감시 시장 규모, 점유율, 동향 분석 보고서 : 제품 수명주기별, 서비스 제공업체별, 유형별, 치료 영역별, 프로세스 흐름별, 최종 용도별, 지역별, 부문별 예측(2024-2030년)

Pharmacovigilance Market Size, Share & Trends Analysis Report By Product Life Cycle, By Service Provider (In-house, Contract Outsourcing), By Type, By Therapeutic Area, By Process Flow, By End Use, By Region, And Segment Forecasts, 2024 - 2030
발행일: | 리서치사: Grand View Research | 페이지 정보: 영문 295 Pages | 배송안내 : 2-10일 (영업일 기준)

    
    
    




※ 본 상품은 영문 자료로 한글과 영문 목차에 불일치하는 내용이 있을 경우 영문을 우선합니다. 정확한 검토를 위해 영문 목차를 참고해주시기 바랍니다.

약물감시 시장 성장과 동향

Grand View Research, Inc.의 최신 보고서에 따르면, 세계 약물감시 시장 규모는 2030년까지 117억 8,000만 달러에 달할 것으로 예측됩니다.

2024년부터 2030년까지 연평균 6.8%의 성장률을 보일 것으로 예상됩니다. 시장 성장의 주요 요인은 부작용(ADR) 발생률의 증가로, ADR은 의료 시스템에 큰 부담을 주며 선진국의 이환율의 명백한 근거 중 하나입니다. 미국 국립생물공학정보센터(NCBI)에 따르면, 유럽에서는 연간 입원 환자 약 20명 중 1명이 ADR로 인해 입원하고 있습니다. 약물감시(PV) 서비스는 의약품과 관련된 부작용을 인지할 수 있도록 제조업체를 지원함으로써 임상시험 단계에서 중요한 역할을 하고 있습니다.

또한, 2022년 2월 Journal of Current Medicine Research and Practice지에 게재된 논문 'Characterization of Seriousness and Outcome of Adverse Drug Reactions in Patients Receiving Cancer Chemotherapy Drugs-A Prospective Observational Study(암 화학요법제를 투여받는 환자에서 부작용의 심각성과 결과의 특성 - 전향적 관찰 연구)'에 따르면, 미국에서는 매년 ADR로 인해 연간 10만 명 이상이 사망하고 있으며, 지난 10년간 건강상의 큰 문제가 되고 있는 것으로 나타났습니다. 치명적인 부정맥, 간부전 등 ADR은 의약품 사용과 관련된 위험이 관련 이익을 능가하기 때문에 의약품의 시장 철수로 이어질 수 있으며, COVID-19 팬데믹은 PV 서비스 제공업체에 기회와 도전을 동시에 가져왔고, 경쟁력을 강화하기 위한 혁신적인 플랫폼의 개발로 이어졌습니다.

예를 들어, 2020년 12월 생명과학 산업 상용 서비스 제공업체인 EVERSANA는 의약품 개발 프로세스 자동화를 전문으로 하는 생명과학 소프트웨어 회사인 ArisGlobal과 제휴했습니다. 이번 제휴는 엔드 투 엔드 PV 절차를 디지털화하여 전 세계적으로 보다 안전하고 효과적인 의료 서비스를 제공하는 것을 목표로 합니다. 클라우드 기반 PV 및 의약품 안전 플랫폼과 같이 기술적으로 진보하고 사용자 친화적인 소프트웨어 시스템 시장은 예측 기간 동안 업계의 성장을 지원할 것으로 예상됩니다. 예를 들어, Clinevo Technologies는 사례 처리, 의약품 신청/AS2 게이트웨이, PV 섭취, 분석, 안전 신호 등 다양한 기능을 포괄하는 클라우드 기반 솔루션인 Clinevo Safety를 제공하고 있습니다.

올인원 플랫폼이 시장을 주도하고 있습니다. 또한, 조직적인 노력이 브라질과 같은 신흥 시장의 성장을 뒷받침하고 있습니다. 예를 들어, 브라질에서는 FIPFARMA(Fundacao Instituto de Pesquisas Farmaceuticas)와 Pharmacy College(Universidade de Sao Paulo)가 제공하는 환자 안전 및 PV 프로그램을 통해 제약 업계, 학계, 임상 현장 및 보건 당국이 참여하는 환자 안전 및 PV 프로그램을 도입했습니다. Universidade de Sao Paulo)가 제공하는 이 프로그램은 두 코호트(2020년과 2022년)에 걸쳐 30시간의 온라인 코스를 진행했습니다. 이 과정에서는 의료 및 약물감시 개요, 의약품 안전 및 관리, 환자 안전 문화 등 중요한 주제를 다루었습니다. 워크숍에서는 의료 전문가(HCP)가 직면한 실제 문제를 다루고 공동으로 문제를 해결하도록 장려했습니다.

화상회의는 HCP를 효과적으로 참여시키고, 교육하고, 지식 공유를 촉진하고, 사고방식의 전환을 촉진했습니다. 이 이니셔티브는 참가자들에게 긍정적인 영향을 미치고 브라질의 PV 관행을 강화했습니다. 선진국의 주요 제약사들은 비용 절감과 운영비 절감을 위해 PV 서비스 아웃소싱에 집중하고 있습니다. 이는 개발도상국의 CRO(임상시험수탁기관)가 업계 점유율을 확대할 수 있는 기회를 창출할 것으로 예상됩니다. 제약사들은 전 세계적으로 증가하는 환자 수요를 충족시키기 위해 제품 개발 절차를 재검토하고 있습니다. 이러한 요인들로 인해 PV 서비스에 대한 수요는 예측 기간 동안 증가할 것으로 예상됩니다.

또한, PV 업계 기업들은 인수, 제휴, 사업 확장, 제품 출시 등의 전략을 통해 제품 범위를 넓히고 시장에서의 입지를 강화하는 데 주력하고 있습니다. 예를 들어, 제약 산업 전문 서비스 제공업체인 Ergomed plc는 2022년 2월 ADAMAS Consulting Group Limited를 인수했으며, ADAMAS는 의약품 제조, 임상시험 감사 및 PV 시스템 품질 보증 서비스를 제공하는 국제적인 컨설팅 회사입니다. 인수 금액은 2,560만 파운드(GBP)로, 향후 에르고메드의 수익에 긍정적인 영향을 미칠 것으로 예상되며, 향후 추가적인 성장과 전략적 우위를 확보할 수 있을 것으로 기대됩니다.

약물감시 시장 보고서 하이라이트

  • 2023년 Phase IV가 75.85% 이상의 매출 점유율로 시장을 장악했습니다. 이는 ADR 사고의 증가와 시판 후 조사로 인한 것입니다.
  • 제약기업이 서비스 아웃소싱을 통해 운영비용을 절감하기 위해 2023년 서비스 제공업체 분야 시장 점유율은 아웃소싱 위탁이 60.63%를 넘어섰습니다.
  • 자발적 보고 부문은 2023년 매출 점유율 30.22% 이상으로 시장을 주도했습니다. 이 분야는 신규, 중증, 희귀 ADR을 효율적이고 비용 효율적으로 탐지하는 데 사용됩니다.
  • 2023년 치료 영역 부문에서는 만성 암 치료에 대한 바이오 제약사의 연구 노력에 힘입어 암 분야가 26.95% 이상의 점유율을 차지하며 가장 큰 비중을 차지했습니다.
  • 사례 데이터 관리는 예측 기간 동안 프로세스 흐름 분야에서 가장 빠른 CAGR 7.3%로 성장할 것으로 예상됩니다.
  • 최종 용도 부문에서는 생명공학 기업이 가장 빠른 CAGR 8.0%로 성장할 것으로 예상됩니다. 이는 생물학적 제제, 치료제, 유전자 치료제 등 신제품 연구개발에 집중하고 있기 때문입니다.
  • 북미는 신약 개발에 대한 투자, 유리한 규제, 연구 단위 및 임상시험의 강력한 존재로 인해 2023년 32.55% 이상의 가장 큰 매출 점유율을 차지했습니다.
  • 각 기업은 경쟁 우위를 확보하기 위해 신제품 출시, 제휴, 인수 등의 전략을 채택하고 있습니다.

목차

제1장 조사 방법과 범위

제2장 주요 요약

제3장 약물감시 시장 변수, 동향, 범위

  • 시장 계통 전망
    • 상부 시장 분석
    • 보조 시장 분석
  • 침투와 성장 전망 매핑
  • 약물감시 시장 역학
    • 시장 성장 촉진요인 분석
    • 시장 성장 억제요인 분석
    • 업계 과제
  • 약물감시 시장 분석 툴 : 포터
  • SWOT 분석, 요인별(정치·법률, 경제, 기술)
  • 밸류체인 분석
    • 전임상
    • 임상
    • PMA
  • 서비스 제공과 그 수요에 대한 수명주기 매핑
  • 규제 프레임워크
    • 국가별 규제기관 리스트
  • 조직 구조 소개
  • 가격 모델
    • 활동별 의약품 안전 예산 배분
    • 개발 단계별
    • 치료 분야별
    • 가격 레벨
  • 기술 타임라인 개요
    • 기술 변화와 채용
  • COVID-19의 영향
    • 최근의 동향과 전략적 성과
    • 기업이 실시하는 전략
  • 시장 동향
    • 자원 스케일링
    • 약물감시 자동화
  • 인플레이션의 영향
  • 메디컬 라이팅과 의료 안전 리뷰의 비교 분석
    • 2022년 메디컬 라이팅 시장 전망
    • 의료 안전 리뷰 시장 전망, 2022년

제4장 약물감시 시장 : 제품수명주기별 추정·동향 분석

  • 제품수명주기별 시장 점유율 분석, 2022년 및 2030년
  • 제품수명주기 대시보드
  • 시장 정의와 범위

제5장 약물감시 시장 : 서비스 프로바이더 추정·동향 분석

  • 서비스 프로바이더별 시장 점유율 분석, 2023년 및 2030년
  • 서비스 프로바이더 대시보드
  • 시장 정의와 범위

제6장 약물감시 시장 : 유형별 추정·동향 분석

  • 유형별 시장 점유율 분석, 2023년 및 2030년
  • 유형 대시보드
  • 시장 정의와 범위

제7장 약물감시 시장 : 프로세스 플로우별 추정·동향 분석

  • 프로세스 플로우별 시장 점유율 분석, 2023년 및 2030년
  • 프로세스 플로우 대시보드
  • 시장 정의와 범위

제8장 약물감시 시장 : 치료 분야별 추정·동향 분석

  • 치료 분야별 시장 점유율 분석, 2023년 및 2030년
  • 치료 분야 대시보드
  • 시장 정의와 범위

제9장 약물감시 시장 : 최종 용도별 추정·동향 분석

  • 최종 용도별 시장 점유율 분석, 2023년 및 2030년
  • 최종 용도 대시보드
  • 시장 정의와 범위

제10장 약물감시 시장 : 지역별 추정·동향 분석, 제품, 서비스 프로바이더, 유형, 최종 용도별

  • 지역별 시장 현황
  • 북미
  • 유럽
  • 아시아태평양
  • 라틴아메리카
  • 중동 및 아프리카

제11장 약물감시 시장 : 경쟁 분석

  • 시장 참여 분류
  • 공개 기업
  • 비공개 기업
  • 경쟁 요인과 전략
  • 약물감시 서비스를 이용하는 헬스케어 기업

제12장 경쟁 상황

  • 기업 개요
    • ACCENTURE
    • CLINQUEST GROUP BV(LINICAL AMERICAS)
    • IQVIA Inc.
    • COGNIZANT
    • LABORATORY CORPORATION OF AMERICA HOLDINGS
    • IBM
    • ARISGLOBAL
    • ICON PLC.
    • CAPGEMINI
    • ITCLINICAL
    • TAKE SOLUTIONS LIMITED
    • PAREXEL INTERNATIONAL CORPORATION.
    • BIOCLINICA, INC.
    • WIPRO
    • UNITED BIOSOURCE LLC
    • FMD K&L(CLINCHOICE)

제13장 성공 전략

  • 주요 성공/스코어링 기준
    • 카테고리별
  • 벤더 선택의 주요 요소
    • 카테고리별
    • 기업 규모별

제14장 스위칭 비용 분석

ksm 24.07.18

Pharmacovigilance Market Growth & Trends:

The global pharmacovigilance market size is projected to reach USD 11.78 billion by 2030, according to a new report by Grand View Research, Inc. It is anticipated to witness growth at a CAGR of 6.8% from 2024 to 2030. The key factor responsible for the market growth is the growing incidence of Adverse Drug Reactions (ADR). ADR imposes a significant load on healthcare systems and is one of the evident grounds for morbidity in developed nations. As per the National Center for Biotechnology Information (NCBI), about 1 in 20 hospitalizations in Europe yearly are owing to ADR. Pharmacovigilance (PV) services play a vital role in the clinical trial phase by aiding manufacturers in recognizing the negative consequences associated with the drug.

Furthermore, a February 2022 article published in the Journal of Current Medicine Research and Practice titled "Characterization of Seriousness and Outcome of Adverse Drug Reactions in Patients Receiving Cancer Chemotherapy Drugs - A Prospective Observational Study" revealed that serious ADRs in the U.S. result in over 100,000 deaths annually and have been a major health concern since the past decade. ADRs, such as fatal arrhythmia and liver failure, can result in drug withdrawal from the market as the risks related to the drug usage outweigh its associated benefits. The COVID-19 pandemic presented both opportunities and challenges for PV service providers, leading to the development of innovative platforms for a competitive edge.

For instance, in December 2020, EVERSANA, a commercial services provider in the life sciences industry, collaborated with ArisGlobal, a life sciences software company specializing in automating drug development processes. This partnership was aimed to digitally transform end-to-end PV procedures, ensuring safer and more effective healthcare worldwide. The market for technologically advanced and user-friendly software systems, like cloud-based PV and drug safety platforms, is anticipated to support industry growth over the forecast period. For instance, Clinevo Technologies offers Clinevo Safety, a cloud-based solution encompassing various functionalities, such as Case Processing, Regulatory Submissions/AS2 Gateway, PV Intake, Analytics, and Safety Signals.

This all-in-one platform is driving the market forward. Furthermore, organizational initiatives support the growth of emerging markets like Brazil. For instance, a collaborative Patient Safety and PV program was introduced in Brazil, involving the pharmaceutical industry, academia, clinical practice, and health authorities. Offered by FIPFARMA (Fundacao Instituto de Pesquisas Farmaceuticas) and Pharmacy College (Universidade de Sao Paulo), the program conducted a 30-hour online course in two cohorts (2020 and 2022). It covered crucial topics, such as Healthcare and Pharmacovigilance Overview, Drug Safety & Management, and Patient Safety Culture. Workshops addressed real Challenges Healthcare Professionals (HCPs) faced and encouraged collaborative problem-solving.

Video conferences effectively engaged and educated HCPs, facilitating knowledge sharing and promoting a mindset shift. This initiative positively impacted participants and enhanced PV practices in Brazil. Key pharma companies in developed nations are concentrating on outsourcing PV services to decrease costs and reduce operational expenses. This is expected to create an opportunity for Contact Research Organizations (CROs) in developing territories to acquire more industry share. Manufacturers are renovating their product development procedures to fulfill the growing patient needs worldwide. These factors are predicted to augment the demand for PV services over the forecast period.

Furthermore, PV industry players are implementing strategies like acquisitions, collaborations, expansions, and product launches to broaden their offerings and expand their market presence. For example, in February 2022, Ergomed plc, a specialized services provider to the pharmaceutical industry, acquired ADAMAS Consulting Group Limited. ADAMAS is an international consultancy that offers quality assurance services in pharmaceutical manufacturing, clinical trial auditing, and PV systems. The acquisition, valued at £25.6 million (in pounds), is expected to favor Ergomed's earnings, with further growth and strategic advantages anticipated in the future.

Pharmacovigilance Market Report Highlights:

  • Phase IV dominated the market with a revenue share of over 75.85% in 2023. This was driven by increased ADR incidents and post-marketing surveillance
  • Contract outsourcing accounted for over 60.63% market share in the service provider segment in 2023, as pharmaceutical organizations aimed to reduce operational costs by outsourcing services
  • The spontaneous reporting type segment led the market with a revenue share of over 30.22% in 2023. Its applications include efficient and cost-effective detection of new, serious, and rare ADRs
  • Oncology held the largest share of over 26.95% in the therapeutic area segment in 2023, fueled by biopharmaceutical companies' research efforts in chronic cancer treatments
  • Case data management is anticipated to grow at the fastest CAGR of 7.3% in the process flow segment during the forecast period
  • Biotechnology companies are expected to have the fastest CAGR of 8.0% in the end-use segment. This is due to their focus on R&D for novel products, such as biologics, therapies, and gene therapies
  • North America held the largest revenue share of over 32.55% in 2023 due to investments in new drug development, favorable regulations, and a strong presence of research units and clinical trials
  • Companies are adopting strategies like new product launches, collaborations, and acquisitions to gain a competitive advantage

Table of Contents

Chapter 1 Research Methodology & Scope

  • 1.1 Market Segmentation & Scope
    • 1.1.1 Product Life Cycle
    • 1.1.2 Service Provider
    • 1.1.3 Type
    • 1.1.4 Process Flow
    • 1.1.5 Therapeutic Area
    • 1.1.6 End Use
    • 1.1.7 Regional Scope
    • 1.1.8 Estimates and Forecast Timeline
  • 1.2 Research Methodology
  • 1.3 Information Procurement
    • 1.3.1 Purchased Database:
    • 1.3.2 GVR's Internal Database
    • 1.3.3 Secondary Sources
    • 1.3.4 Primary Research:
    • 1.3.5 Details Of Primary Research
      • 1.3.5.1 Data for primary interviews in North America
      • 1.3.5.2 Data for Primary Interviews in Europe
      • 1.3.5.3 Data for Primary Interviews in Asia Pacific
      • 1.3.5.4 Data for Primary Interviews in Latin America
      • 1.3.5.5 Data for Primary Interviews in Middle East & Africa
  • 1.4 Information or Data Analysis
    • 1.4.1 Data Analysis Models
  • 1.5 Market Formulation & Validation
  • 1.6 Model Details
    • 1.6.1 Commodity Flow Analysis
      • 1.6.1.1 Top down market estimation
      • 1.6.1.2 CAGR Calculation
      • 1.6.1.3 Key Report Updates
  • 1.7 List of Secondary Sources
  • 1.8 List of Abbreviations
  • 1.9 Market Definitions
  • 1.10 Report Objectives
    • 1.10.1 Objective 1:
    • 1.10.2 Objective 2:

Chapter 2 Executive Summary

  • 2.1 Market Snapshot
  • 2.2 Segment Snapshot (Product Life Cycle & Service Provider)
  • 2.3 Segment Snapshot (Type & Therapeutic Area)
  • 2.4 Segment Snapshot (Process Flow & End Use)
  • 2.5 Competitive Landscape Snapshot

Chapter 3 Pharmacovigilance Market Variables, Trends & Scope

  • 3.1 Market Lineage Outlook
    • 3.1.1 Parent Market Analysis
    • 3.1.2 Ancillary Market Analysis
  • 3.2 Penetration & Growth Prospect Mapping
  • 3.3 Pharmacovigilance Market Dynamics
    • 3.3.1 Market Driver Analysis
      • 3.3.1.1 Growing drug consumption and drug development rates
      • 3.3.1.2 Increasing incidence of ADR and drug toxicity
      • 3.3.1.3 Increasing trend of outsourcing pharmacovigilance services
      • 3.3.1.4 Increasing externalization of clinical trial studies by large pharmaceutical and biopharmaceutical companies
      • 3.3.1.5 Increasing regulatory Burden on Manufacturers
      • 3.3.1.6 Introduction of technologically advanced software services
      • 3.3.1.7 Constantly rising investment on R&D by healthcare companies
      • 3.3.1.8 Partnerships and collaborations between market players
    • 3.3.2 Market Restraint Analysis
      • 3.3.2.1 Shortage of skilled labor
      • 3.3.2.2 Expensive technology for small and mid-sized player
      • 3.3.2.3 Lack of recognition
      • 3.3.2.4 Scarcity of integration standards
    • 3.3.3 Industry Challenges
  • 3.4 Pharmacovigilance Market Analysis Tools: Porters
  • 3.5 SWOT Analysis, by Factor (Political & Legal, Economic, and Technological)
  • 3.6 Value Chain Analysis
    • 3.6.1 Preclinical
    • 3.6.2 Clinical
    • 3.6.3 PMA
  • 3.7 Mapping of Life Cycle against Service Offering and Their Demand
  • 3.8 Regulatory Framework
    • 3.8.1 List of Regulatory Bodies by Country
  • 3.9 Organization Structure Introduction
  • 3.10 Pricing Models
    • 3.10.1 Drug Safety Budget Allocation by Activities
    • 3.10.2 By Development Phase
    • 3.10.3 By Therapeutic Area
    • 3.10.4 Pricing Level
      • 3.10.4.1 Project management
      • 3.10.4.2 Case processing
      • 3.10.4.3 ADR Reporting
      • 3.10.4.4 Medical writing
      • 3.10.4.5 Drug safety management
  • 3.11 Technology Timeline Overview
    • 3.11.1 Changing Technology & Adoption
      • 3.11.1.1 Social Media
      • 3.11.1.2 Literature screening
      • 3.11.1.3 Automation and AI
      • 3.11.1.4 Big data analytics in PV
  • 3.12 Impact of COVID-19
    • 3.12.1 Recent Developments & Strategic Outcomes
      • 3.12.1.1 Regulatory requirements/changes due to covid-19
    • 3.12.2 Strategies Implemented by Companies
      • 3.12.2.1 IQVIA
      • 3.12.2.2 PARAXEL International Corporation
      • 3.12.2.3 Bioclinica
      • 3.12.2.4 Pharmaceutical Product Development (PPD)
      • 3.12.2.5 IBM Corporation
      • 3.12.2.6 ICON, plc
      • 3.12.2.7 PRA Health Sciences
      • 3.12.2.8 Covance Inc.
      • 3.12.2.9 ArisGlobal
      • 3.12.2.10 Linical Accelovance
      • 3.12.2.11 Laboratory Corporation of America Holdings
  • 3.13 Market Trends
    • 3.13.1 Scaling Of Resources
    • 3.13.2 Automation in Pharmacovigilance
  • 3.14 Impact of Inflation
  • 3.15 Comparative Analysis between Medical Writing vs Medical Safety Review
    • 3.15.1 Medical Writing Market Outlook, 2022
      • 3.15.1.1 Medical writing Market estimates and forecasts, 2018 - 2030 (USD Million)
    • 3.15.2 Medical Safety Review Market Outlook, 2022
      • 3.15.2.1 Medical Safety Review market estimates and forecasts, 2018 - 2030 (USD Million)

Chapter 4 Pharmacovigilance Market: Product Life Cycle Estimates & Trend Analysis

  • 4.1 Product Life Cycle Market Share Analysis, 2022 & 2030
  • 4.2 Product Life Cycle Dashboard
  • 4.3 Market definition and scope
    • 4.3.1 Preclinical
      • 4.3.1.1 Preclinical market estimates and forecasts, 2018 - 2030 (USD Million)
    • 4.3.2 Phase I
      • 4.3.2.1 Phase I market estimates and forecasts, 2018 - 2030 (USD Million)
    • 4.3.3 Phase II
      • 4.3.3.1 Phase II market estimates and forecasts, 2018 - 2030 (USD Million)
    • 4.3.4 Phase III
      • 4.3.4.1 Phase III market estimates and forecasts, 2018 - 2030 (USD Million)
    • 4.3.5 Phase IV
      • 4.3.5.1 Phase IV market estimates and forecasts, 2018 - 2030 (USD Million)

Chapter 5 Pharmacovigilance Market: Service Provider Estimates & Trend Analysis

  • 5.1 Service provider Market Share Analysis, 2023 & 2030
  • 5.2 Service Provider Dashboard
  • 5.3 Market definition and scope
    • 5.3.1 IN HOUSE
      • 5.3.1.1 In house market estimates and forecasts, 2018 - 2030 (USD Million)
    • 5.3.2 Contract Outsourcing
      • 5.3.2.1 Contract outsourcing market estimates and forecasts, 2018 - 2030 (USD Million)

Chapter 6 Pharmacovigilance Market: Type Estimates & Trend Analysis

  • 6.1 Type Market Share Analysis, 2023 & 2030
  • 6.2 Type Dashboard
  • 6.3 Market definition and scope
    • 6.3.1 Spontaneous Reporting
      • 6.3.1.1 Spontaneous Reporting market estimates and forecasts, 2018 - 2030 (USD Million)
    • 6.3.2 Intensified ADR Reporting
      • 6.3.2.1 Intensified ADR Reporting market estimates and forecasts, 2018 - 2030 (USD Million)
    • 6.3.3 Targeted Spontaneous Reporting
      • 6.3.3.1 Targeted spontaneous reporting market estimates and forecasts, 2018 - 2030 (USD Million)
    • 6.3.4 Cohort Event Monitoring (CEM)
      • 6.3.4.1 CEM market estimates and forecasts, 2018 - 2030 (USD Million)
    • 6.3.5 EHR Mining
      • 6.3.5.1 EHR Mining market estimates and forecasts, 2018 - 2030 (USD Million)

Chapter 7 Pharmacovigilance Market: Process Flow Estimates & Trend Analysis

  • 7.1 Process Flow Market Share Analysis, 2023 & 2030
  • 7.2 Process Flow Dashboard
  • 7.3 Market definition and scope
    • 7.3.1 Case Data Management
      • 7.3.1.1 Case data management market estimates and forecasts, 2018 - 2030 (USD Million)
      • 7.3.1.1.1 Case logging
      • 7.3.1.1.1.1 Case logging market estimates and forecasts, 2018 - 2030 (USD Million)
      • 7.3.1.1.2 Case data analysis
      • 7.3.1.1.2.1 Case data analysis market estimates and forecasts, 2018 - 2030 (USD Million)
      • 7.3.1.1.3 Medical reviewing and reporting
      • 7.3.1.1.3.1 Medical reviewing and reporting market estimates and forecasts, 2018 - 2030 (USD Million)
    • 7.3.2 Signal Detection
      • 7.3.2.1 Signal detection market estimates and forecasts, 2018 - 2030 (USD Million)
      • 7.3.2.1.1 Adverse event logging
      • 7.3.2.1.1.1 Adverse Event Logging market estimates and forecasts, 2018 - 2030 (USD Million)
      • 7.3.2.1.2 Adverse Event Analysis
      • 7.3.2.1.2.1 Adverse Event Analysis market estimates and forecasts, 2018 - 2030 (USD Million)
      • 7.3.2.1.3 Adverse Event Review & Reporting
      • 7.3.2.1.3.1 Adverse Event Review & Reporting market estimates and forecasts, 2018 - 2030 (USD Million)
    • 7.3.3 Risk Management System
      • 7.3.3.1 Risk Management System market estimates and forecasts, 2018 - 2030 (USD Million)
      • 7.3.3.1.1 Risk Evaluation System
      • 7.3.3.1.1.1 Risk Evaluation System market estimates and forecasts, 2018 - 2030 (USD Million)
      • 7.3.3.1.2 Risk Mitigation System
      • 7.3.2.1.2.1 Risk Mitigation System market estimates and forecasts, 2018 - 2030 (USD Million)

Chapter 8 Pharmacovigilance Market: Therapeutic Area Estimates & Trend Analysis

  • 8.1 Therapeutic Area Market Share Analysis, 2023 & 2030
  • 8.2 Therapeutic Area Dashboard
  • 8.3 Market definition and scope
    • 8.3.1 Oncology
      • 8.3.1.1 Oncology market estimates and forecasts, 2018 - 2030 (USD Million)
    • 8.3.2 Neurology
      • 8.3.2.1 Neurology market estimates and forecasts, 2018 - 2030 (USD Million)
    • 8.3.3 Cardiology
      • 8.3.3.1 Cardiology market estimates and forecasts, 2018 - 2030 (USD Million)
    • 8.3.4 Respiratory Systems
      • 8.3.4.1 Respiratory systems market estimates and forecasts, 2018 - 2030 (USD Million)
    • 8.3.5 Others
      • 8.3.5.1 Others market estimates and forecasts, 2018 - 2030 (USD Million)

Chapter 9 Pharmacovigilance Market: End Use Estimates & Trend Analysis

  • 9.1 End Use Market Share Analysis, 2023 & 2030
  • 9.2 End Use Dashboard
  • 9.3 Market definition and scope
    • 9.3.1 Pharmaceuticals
      • 9.3.1.1 Pharmaceuticals market estimates and forecasts, 2018 - 2030 (USD Million)
    • 9.3.2 Biotechnology Companies
      • 9.3.2.1 Biotechnology companies market estimates and forecasts, 2018 - 2030 (USD Million)
    • 9.3.3 Medical Device Manufacturers
      • 9.3.3.1 Medical Device Manufacturers market estimates and forecasts, 2018 - 2030 (USD Million)
    • 9.3.4 Others
      • 9.3.4.1 Others market estimates and forecasts, 2018 - 2030 (USD Million)

Chapter 10 Pharmacovigilance Market: Regional Estimates & Trend Analysis, By, Product, Service Providers, Type, and End Use

  • 10.1 Regional Market Snapshot
  • 10.2 North America
    • 10.2.1 North America Pharmacovigilance Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 10.2.2 U.S.
      • 10.2.2.1 U.S. Pharmacovigilance market estimates and forecasts, 2018- 2030 (USD Million)
      • 10.2.2.2 Competitive scenario
      • 10.2.2.3 Regulatory Framework
    • 10.2.3 Canada
      • 10.2.3.1 Canada Pharmacovigilance market estimates and Forecasts, 2018 - 2030 (USD Million)
      • 10.2.3.2 Competitive scenario
      • 10.2.3.3 Regulatory Framework
  • 10.3 Europe
    • 10.3.1 Europe Pharmacovigilance Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 10.3.2 UK
      • 10.3.2.1 UK Pharmacovigilance market estimates and Forecasts, 2018 - 2030 (USD Million)
      • 10.3.2.2 Competitive scenario
      • 10.3.2.3 Regulatory Framework
    • 10.3.3 Germany
      • 10.3.3.1 Germany Pharmacovigilance market estimates and forecasts, 2018 - 2030 (USD Million
      • 10.3.3.2 Competitive scenario
      • 10.3.3.3 Regulatory Framework
    • 10.3.4 France
      • 10.3.4.1 France Pharmacovigilance market estimates and forecasts, 2018- 2030 (USD Million)
      • 10.3.4.2 Competitive scenario
      • 10.3.4.3 Regulatory Framework
    • 10.3.5 Italy
      • 10.3.5.1 Italy Pharmacovigilance market estimates and forecasts, 2018 - 2030 (USD Million)
      • 10.3.5.2 Competitive scenario
      • 10.3.5.3 Regulatory Framework
    • 10.3.6 Spain
      • 10.3.6.1 Spain pharmacovigilance market estimates and forecasts, 2018 - 2030 (USD Million)
      • 10.3.6.2 Competitive scenario
      • 10.3.6.3 Regulatory Framework
    • 10.3.7 Russia
      • 10.3.7.1 Russia Pharmacovigilance market estimates and forecasts, 2018- 2030 (USD Million)
      • 10.3.7.2 Competitive scenario
      • 10.3.7.3 Regulatory Framework
    • 10.3.8 Denmark
      • 10.3.8.1 Denmark Pharmacovigilance Market Estimates and Forecasts, 2018 - 2030 (USD Million)
      • 10.3.8.2 Competitive scenario
      • 10.3.8.3 Regulatory Framework
    • 10.3.9 Norway
      • 10.3.9.1 Norway Pharmacovigilance Market Estimates and Forecasts, 2018 - 2030 (USD Million)
      • 10.3.9.2 Competitive scenario
      • 10.3.9.3 Regulatory Framework
    • 10.3.10 Sweden
      • 10.3.10.1 Sweden Pharmacovigilance Market Estimates and Forecasts, 2018 - 2030 (USD Million)
      • 10.3.10.2 Competitive scenario
      • 10.3.10.3 Regulatory Framework
  • 10.4 Asia Pacific
    • 10.4.1 Asia Pacific Pharmacovigilance Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 10.4.2 JAPAN
      • 10.4.2.1 Japan Pharmacovigilance Market Estimates and Forecasts, 2018 - 2030 (USD Million)
      • 10.4.2.2 Competitive scenario
      • 10.4.2.3 Regulatory Framework
    • 10.4.3 CHINA
      • 10.4.3.1 China Pharmacovigilance Market Estimates and Forecasts, 2018 - 2030 (USD Million)
      • 10.4.3.2 Competitive Scenario
      • 10.4.3.3 Regulatory Framework
    • 10.4.4 India
      • 10.4.4.1 India Pharmacovigilance Market Estimates and Forecasts, 2018 - 2030 (USD Million)
      • 10.4.4.2 Competitive Scenario
      • 10.4.4.3 Regulatory Framework
    • 10.4.5 Australia
      • 10.4.5.1 Australia Pharmacovigilance Market Estimates and Forecasts, 2018 - 2030 (USD Million)
      • 10.4.5.2 Competitive Scenario
      • 10.4.5.3 Regulatory Framework
    • 10.4.6 Thailand
      • 10.4.6.1 Thailand Pharmacovigilance Market Estimates and Forecasts, 2018 - 2030 (USD Million)
      • 10.4.6.2 Competitive Scenario
      • 10.4.6.3 Regulatory Framework
    • 10.4.7 South Korea
      • 10.4.7.1 South Korea Pharmacovigilance Market Estimates and Forecasts, 2018 - 2030 (USD Million)
      • 10.4.7.2 Competitive Scenario
      • 10.4.7.3 Regulatory Framework
  • 10.5 Latin America
    • 10.5.1 Latin America Pharmacovigilance Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 10.5.2 Brazil
      • 10.5.2.1 Brazil Pharmacovigilance Market Estimates and Forecasts, 2018 - 2030 (USD Million)
      • 10.5.2.2 Competitive Scenario
      • 10.5.2.3 Regulatory Framework
    • 10.5.3 Mexico
      • 10.5.3.1 Mexico Pharmacovigilance Market Estimates and Forecasts, 2018 - 2030 (USD Million)
      • 10.5.3.2 Competitive Scenario
      • 10.5.3.3 Regulatory Framework
    • 10.5.4 Argentina
      • 10.5.4.1 Argentina Pharmacovigilance Market Estimates and Forecasts, 2018 - 2030 (USD Million)
      • 10.5.4.2 Competitive Scenario
      • 10.5.4.3 Regulatory Framework
  • 10.6 MEA
    • 10.6.1 MEA Pharmacovigilance Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 10.6.2 South Africa
      • 10.6.2.1 South Africa Pharmacovigilance Market Estimates and Forecasts, 2018 - 2030 (USD Million)
      • 10.6.2.2 Competitive Scenario
      • 10.6.2.3 Regulatory Framework
    • 10.6.3 Saudi Arabia
      • 10.6.3.1 Saudi Arabia Pharmacovigilance Market Estimates and Forecasts, 2018- 2030 (USD Million)
      • 10.6.3.2 Competitive Scenario
      • 10.6.3.3 Regulatory Framework
    • 10.6.4 UAE
      • 10.6.4.1 UAE Arabia Pharmacovigilance Market Estimates and Forecasts, 2018- 2030 (USD Million)
      • 10.6.4.2 Competitive Scenario
      • 10.6.4.3 Regulatory Framework
    • 10.6.5 Kuwait
      • 10.6.5.1 Kuwait Pharmacovigilance Market Estimates and Forecasts, 2018- 2030 (USD Million)
      • 10.6.5.2 Competitive Scenario
      • 10.6.5.3 Regulatory Framework

Chapter 11 Pharmacovigilance Market: Competitive Analysis

  • 11.1 Market Participation Categorization
  • 11.2 Public Companies
    • 11.2.1 Company Market Position Analysis
    • 11.2.2 Company Market Share
  • 11.3 Private Companies
    • 11.3.1 List of Key Emerging Companies
  • 11.4 Competitive Factors and Strategies
    • 11.4.1 Increasing strategic collaborations and product launch
    • 11.4.2 Strategic Government initiatives which include collaborations
    • 11.4.3 Competitors increased PV awareness program
    • 11.4.4 Competitors increased collaboration and outsourcing of operations
    • 11.4.5 Consolidation Trends
  • 11.5 Healthcare Companies Using Pharmacovigilance Services
    • 11.5.1 Potential Customers
    • 11.5.2 Notable Cases
      • 11.5.2.1 Case Study 1
      • 11.5.2.1.1 Case Study 1
      • 11.5.3.1.2 Case Study 2
      • 11.5.2.2 Case Study 2
      • 11.5.2.3 Case Study 3
      • 11.5.3.4 Case Study 4
    • 11.5.3 Key Focus areas for the pharmaceutical/healthcare companies
      • 11.5.3.1 Adoption of technological advancements in life sciences industry
      • 11.5.3.2 Published survey insights - related to adoption of pharmacovigilance automation

Chapter 12 Competitive Landscape

  • 12.1 Company Profiles
    • 12.1.1 ACCENTURE
      • 12.1.1.1 Company overview
      • 12.1.1.2 Service benchmarking
      • 12.1.1.3 Financial performance
      • 12.1.1.4 Strategic initiatives
      • 12.1.1.5 SWOT Analysis
    • 12.1.2 CLINQUEST GROUP B.V. (LINICAL AMERICAS)
      • 12.1.2.1 Company overview
      • 12.1.2.2 Service benchmarking
      • 12.1.2.3 Financial performance
      • 12.1.2.4 Strategic initiatives
      • 12.1.2.5 SWOT Analysis
    • 12.1.3 IQVIA Inc.
      • 12.1.3.1 Company overview
      • 12.1.3.2 Service benchmarking
      • 12.1.3.3 Financial performance
      • 12.1.3.4 Strategic initiatives
      • 12.1.3.5 SWOT Analysis
    • 12.1.4 COGNIZANT
      • 12.1.4.1 Company overview
      • 12.1.4.2 Service benchmarking
      • 12.1.4.3 Financial performance
      • 12.1.4.4 Strategic initiatives
      • 12.1.4.5 SWOT Analysis
    • 12.1.5 LABORATORY CORPORATION OF AMERICA HOLDINGS
      • 12.1.5.1 Company overview
      • 12.1.5.2 Service benchmarking
      • 12.1.5.3 Financial performance
      • 12.1.5.4 Strategic initiatives
      • 12.1.5.5 SWOT Analysis
    • 12.1.6 IBM
      • 12.1.6.1 Company overview
      • 12.1.6.2 Service benchmarking
      • 12.1.6.3 Financial performance
      • 12.1.6.4 Strategic initiatives
      • 12.1.6.5 SWOT Analysis
    • 12.1.7 ARISGLOBAL
      • 12.1.7.1 Company Overview
      • 12.1.7.2 Service Benchmarking
      • 12.1.7.3 Financial Performance
      • 12.1.7.4 Strategic Initiatives
      • 12.1.7.5 SWOT Analysis
    • 12.1.8 ICON PLC.
      • 12.1.8.1 Company Overview
      • 12.1.8.2 Service Benchmarking
      • 12.1.8.3 Financial Performance
      • 12.1.8.4 Strategic Initiatives
      • 12.1.8.5 SWOT Analysis
    • 12.1.9 CAPGEMINI
      • 12.1.9.1 Company Overview
      • 12.1.9.2 Service Benchmarking
      • 12.1.9.3 Financial Performance
      • 12.1.9.4 Strategic Initiatives
      • 12.1.9.5 SWOT Analysis
    • 12.1.10 ITCLINICAL
      • 12.1.10.1 Company Overview
      • 12.1.10.2 Service Benchmarking
      • 12.1.10.3 Financial Performance
      • 12.1.10.4 Strategic Initiatives
      • 12.1.10.5 SWOT Analysis
    • 12.1.11 TAKE SOLUTIONS LIMITED
      • 12.1.11.1 Company Overview
      • 12.1.11.2 Service Benchmarking
      • 12.1.11.3 Financial Performance
      • 12.1.11.4 Strategic Initiatives
      • 12.1.11.5 SWOT Analysis
    • 12.1.12 PAREXEL INTERNATIONAL CORPORATION.
      • 12.1.12.1 Company Overview
      • 12.1.12.2 Service Benchmarking
      • 12.1.12.3 Financial Performance
      • 12.1.12.4 Strategic Initiatives
      • 12.1.12.5 SWOT Analysis
    • 12.1.13 BIOCLINICA, INC.
      • 12.1.13.1 Company overview
      • 12.1.13.2 Service benchmarking
      • 12.1.13.3 Financial performance
      • 12.1.13.4 Strategic initiatives
      • 12.1.13.5 SWOT Analysis
    • 12.1.14 WIPRO
      • 12.1.14.1 Company Overview
      • 12.1.14.2 Service Benchmarking
      • 12.1.14.3 Financial Performance
      • 12.1.14.4 Strategic Initiatives
      • 12.1.14.5 SWOT Analysis
    • 12.1.15 UNITED BIOSOURCE LLC
      • 12.1.15.1 Company Overview
      • 12.1.15.2 Service Benchmarking
      • 12.1.15.3 Financial Performance
      • 12.1.15.4 Strategic initiatives
      • 12.1.15.5 SWOT Analysis
    • 12.1.16 FMD K&L (CLINCHOICE)
      • 12.1.16.1 Company Overview
      • 12.1.16.2 Service Benchmarking
      • 12.1.16.3 Financial performance
      • 12.1.16.4 Strategic initiatives
      • 12.1.16.5 SWOT Analysis

Chapter 13 Winning Strategies

  • 13.1 Key Winning/Scoring Criteria
    • 13.1.1 By Categories
      • 13.1.1.1 Pharmaceuticals
      • 13.1.1.2 Biotech companies
      • 13.1.1.3 Medical device companies
  • 13.2 Key Vendor Selection Factors
    • 13.2.1 By Category
    • 13.2.2 By Company Size
      • 13.2.2.1 Key Takeaways

Chapter 14 Switching Cost Analysis

비교리스트
0 건의 상품을 선택 중
상품 비교하기
전체삭제